Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Cancer Kidney Cancer: Vital Size Guide
Cancer Kidney Cancer: Vital Size Guide 4

Knowing the size of a kidney tumor is key to understanding its severity. Tumors bigger than 7 cm are seen as ‘large’. This is because they carry a higher risk of being cancerous and growing aggressively.

Doctors use a system to stage tumors. Tumors above 7 cm fall into T2 (7–10 cm) or T2b (more than 10 cm). This shows they are at a more advanced stage. The size of a tumor greatly affects treatment choices and how well a patient might do. Studies from clinical research show that bigger tumors often have more serious cancer cells and spread beyond the kidney.

Getting a tumor’s size right is vital for good care. Knowing how big a tumor is helps doctors choose the best treatment plan.

Key Takeaways

  • Tumors larger than 7 cm are considered ‘large’ and have a higher risk of malignancy.
  • Clinical staging categorizes tumors above 7 cm as T2 or T2b.
  • The size of a renal mass impacts treatment options and prognosis.
  • Larger tumors have a higher proportion of high-grade tumors and extracapsular extension.
  • Accurate diagnosis and staging are key for effective patient care.

Understanding Kidney Tumors

Cancer Kidney Cancer: Vital Size Guide
Cancer Kidney Cancer: Vital Size Guide 5

Kidney tumors can be benign or malignant, each with its own impact on health. We’ll look at the different types and what they mean for treatment.

Types of Kidney Tumors

Benign vs. Malignant Tumors

Benign tumors are not cancerous and don’t spread. Malignant tumors, on the other hand, are cancerous and can spread. Knowing the difference is key for treatment.

Common Kidney Cancer Types

Renal cell carcinoma (RCC) is the most common kidney cancer in adults, making up about 90% of cases. It includes subtypes like clear cell, papillary, and chromophobe RCC.

Type of Kidney Tumor

Characteristics

Clear Cell RCC

Most common subtype, often associated with good prognosis if caught early

Papillary RCC

Can be multifocal, with variable prognosis

Chromophobe RCC

Rare subtype, generally has a favorable prognosis

Classification of Kidney Tumor Sizes

Cancer Kidney Cancer: Vital Size Guide
Cancer Kidney Cancer: Vital Size Guide 6

Kidney tumor size is key in picking the right treatment. The size of a tumor helps decide how to manage it.

Small Kidney Tumors (≤4 cm)

Small tumors, 4 cm or less, usually have a good outlook. They often don’t cause symptoms and might be found by chance during scans.

Clinical Implications

Small tumors have a low chance of spreading and can often be removed successfully.

Treatment Approaches

For small tumors, treatments like active surveillance, partial removal, or ablative therapies are options. The choice depends on the patient’s health and the tumor’s details.

Medium Kidney Tumors (4-7 cm)

Medium tumors are 4 to 7 cm. They might grow faster and need more careful handling.

Clinical Implications

Medium tumors carry a moderate risk of bad features and might need stronger treatments.

Treatment Approaches

For medium tumors, surgery like partial or radical nephrectomy is common. Other treatments may also be used based on the tumor’s type.

Large Kidney Tumors (>7 cm)

Large tumors are over 7 cm. These have a higher risk of spreading and growing aggressively.

Clinical Implications

Large tumors face a higher risk of spreading and are harder to remove surgically.

Treatment Approaches

Large tumors need a team effort for treatment. This includes surgery and possibly other treatments.

Tumor Size

Clinical Implications

Treatment Approaches

≤4 cm

Lower risk of metastasis

Active surveillance, partial nephrectomy, ablative therapies

4-7 cm

Moderate risk of adverse features

Surgical intervention (partial or radical nephrectomy)

>7 cm

Higher risk of malignancy and metastasis

Multidisciplinary approach, including surgery and adjuvant therapies

Experts say, “The size of the kidney tumor is a critical factor in determining the prognosis and treatment plan” (

This classification helps in standardizing the approach to managing kidney tumors.

).

What Makes a Kidney Tumor “Large”?

The size of a kidney tumor is key in deciding how serious it is and what treatment to use. A tumor is seen as large when it reaches a certain size. This size matters a lot for how well a patient will do and what treatment they need.

The 7 cm Threshold Explained

The 7 cm size is a big deal in kidney tumor sizes. It has changed over time based on new research and studies.

Historical Development of Size Criteria

Over time, doctors have gotten better at classifying kidney tumors. The 7 cm size was picked because studies showed big tumors have a different outlook.

Current Medical Consensus

Today, doctors agree that 7 cm is the size for big kidney tumors. This helps decide how to treat patients and what their chances are.

Impact of Size on Treatment Decisions

The size of a tumor really affects how doctors plan treatment. For example, big tumors might need more serious treatment. Knowing if a tumor can be cured also depends on its size when found.

Surgical Considerations

When planning surgery, tumor size is very important. Bigger tumors need more complicated surgeries. This can affect how well a patient recovers and does in the long run.

Prognostic Implications

The size of a tumor is a big factor in how well a patient will do. Bigger tumors are more likely to spread and have worse outcomes.

Tumor Size (cm)

T Classification

Prognosis

≤4

T1a

Favorable

4-7

T1b

Moderate

>7

T2

Poor

Clinical Staging of Large Kidney Tumors

Staging large kidney tumors is key to picking the right treatment. Tumors are sized, with T2 being split into T2a and T2b.

T2a Classification (7-10 cm)

T2a tumors are 7 to 10 cm big. They are big and need careful checking.

Diagnostic Criteria

To diagnose T2a tumors, CT scans and MRI are used. A biopsy might also be done to check the tumor’s type.

Management Guidelines

T2a tumors usually need surgery, like partial or radical nephrectomy. The surgery type depends on the tumor’s spot and the patient’s health.

T2b Classification (>10 cm)

T2b tumors are over 10 cm. They are very big and hard to treat.

Diagnostic Criteria

Diagnosing T2b tumors uses the same imaging as T2a. It focuses on the tumor’s size and if it’s spreading.

Management Guidelines

T2b tumors need a team effort. This includes surgery and possibly targeted therapy or immunotherapy.

T Classification

Tumor Size

Typical Management

T2a

7-10 cm

Surgical intervention (partial or radical nephrectomy)

T2b

>10 cm

Multidisciplinary approach (surgery, targeted therapy, immunotherapy)

Characteristics of Large Kidney Tumors

Understanding large kidney tumors is key to effective treatment. Research shows these tumors are more likely to be cancerous. This affects treatment choices and patient outcomes.

Benign vs. Malignant Rates

Large kidney tumors tend to be cancerous. Studies reveal a 4% benign rate in these tumors.

The 4% Benign Rate in Large Tumors

This low rate means most large tumors are cancerous. This calls for aggressive treatment.

Implications for Treatment Planning

The high cancer rate in large tumors requires careful planning. Often, surgery is needed.

High-Grade Features

Many large kidney tumors have high-grade features. These features are linked to a poor prognosis.

Understanding the 51% High-Grade Rate

About 51% of these tumors have high-grade features. This shows a more aggressive tumor type.

Impact on Prognosis

High-grade features in large tumors complicate treatment. They also affect survival rates.

Extracapsular Extension

Extracapsular extension is a key feature of large kidney tumors. It affects treatment and prognosis.

The 67% Extracapsular Rate

Approximately 67% of these tumors extend beyond the kidney capsule. This indicates tumor spread.

Clinical Significance

This high rate of extension is critical for surgical planning. It also impacts post-operative care.

Characteristics

Rate

Clinical Implication

Benign Tumors

4%

Low benign rate necessitates aggressive treatment

High-Grade Features

51%

Indicates aggressive tumor biology

Extracapsular Extension

67%

Complicates surgical planning and post-operative management

In conclusion, large kidney tumors, often linked to stage 4 kidney cancer, show aggressive traits. They need thorough evaluation and treatment. A mass on kidney requires detailed investigation due to high cancer risk and adverse features.

Cancer Kidney Cancer: Diagnosis and Evaluation

Diagnosing and evaluating kidney cancer is key to finding the right treatment. We use advanced tools to check the tumor’s details and stage.

Imaging Techniques

Imaging is vital for finding and checking kidney cancer. We use different methods to get clear images of the tumor.

CT Scans and MRI

CT scans and MRI are top choices for kidney cancer imaging. They give us detailed pictures of the tumor’s size, location, and spread. CT scans are great for seeing tumors and how far they’ve spread, while MRI shows soft tissue details.

Ultrasound and Other Modalities

Ultrasound is also useful, mainly for first checks or when other scans can’t be used. In some cases, PET scans help us understand the tumor’s activity.

Biopsy Considerations

Biopsy is a key part of diagnosing kidney cancer, giving us tissue for tests. We think carefully about when to do a biopsy and how to do it.

When Biopsy is Recommended

We usually suggest a biopsy when scans aren’t clear or when we need to confirm cancer before treatment. We look at each case to decide if a biopsy is needed.

Biopsy Techniques and Risks

We use different biopsy methods, like percutaneous biopsy, to get tissue. While safe, biopsies can cause bleeding or infection. We work hard to keep these risks low.

Treatment Approaches for Large Kidney Tumors

When you’re diagnosed with a big kidney tumor, knowing your treatment options is key. The right treatment depends on the tumor’s size, stage, and your health.

Surgical Management

Surgery is often the first step for big kidney tumors. There are two main ways to do surgery:

Radical Nephrectomy

This surgery removes the whole kidney and the tumor. Radical nephrectomy is chosen for bigger tumors or if cancer has spread.

Partial Nephrectomy Considerations

For some, a partial nephrectomy might be an option. This keeps the rest of the kidney by only removing the tumor. It’s for tumors that haven’t spread and you have enough kidney function.

Non-Surgical Alternatives

If surgery isn’t right for you, or you don’t want it, there are other ways to treat your tumor.

Targeted Therapy Options

Targeted therapy uses drugs that attack cancer cells but not healthy ones. It’s used for advanced kidney cancer.

Immunotherapy Approaches

Immunotherapy boosts your immune system to fight cancer. It’s an option for big tumors, even if they’ve spread.

Treatment Option

Description

Typical Use Case

Radical Nephrectomy

Removal of the entire kidney with the tumor

Large tumors or cancer spread

Partial Nephrectomy

Removal of the tumor while preserving the kidney

Localized tumors with sufficient kidney function

Targeted Therapy

Drugs targeting cancer cells specially

Advanced kidney cancer

Immunotherapy

Boosting the immune system to fight cancer

Advanced or metastatic kidney cancer

Knowing your options for treating big kidney tumors is vital. Talking to a doctor can help figure out the best treatment for you.

Prognosis and Survival Rates

The outlook for kidney cancer depends on several things, like the size and grade of the tumor. Knowing these details helps doctors choose the right treatment and predict how well a patient will do.

Factors Affecting Prognosis

Many factors influence how well kidney cancer patients will do. These include:

Tumor Size and Grade

Bigger tumors and those with a higher grade are usually harder to treat. Tumors over 7 cm are considered large and might grow faster.

Patient-Specific Factors

Things like a patient’s overall health, age, and other health issues also matter a lot. These factors help doctors understand how well a patient might do.

5-Year Survival Statistics

Survival rates for kidney cancer depend on when the cancer is found. Knowing these rates helps doctors and patients make better choices.

T2a vs. T2b Outcomes

Patients with T2a tumors (7-10 cm) usually have a better chance of surviving 5 years than those with T2b tumors (over 10 cm).

Impact of Treatment Approach

The treatment chosen can greatly affect how long a patient lives. Surgery, like removing part or all of the kidney, is often the first step for early-stage kidney cancer.

Tumor Classification

5-Year Survival Rate

T2a (7-10 cm)

70-80%

T2b (>10 cm)

50-60%

A leading oncologist says, “Thanks to better surgery and targeted treatments, kidney cancer patients have a better outlook now.”

“Finding cancer early and treating it right are key to better survival chances for kidney cancer patients.”

Multidisciplinary Care at livehospital.com

livehospital.com is committed to top-notch care for kidney cancer patients. Our team creates personalized plans for each patient. This ensures we meet their unique needs.

Internationally Competitive Outcomes

We follow strict standards in treating kidney cancer. Our success rates match the best in the world. This means our patients get the best care possible.

Success Rates and Benchmarks

We check our results against global standards. For example, our 5-year survival rates for kidney cancer patients are among the best. This is backed by studies on kidney cancer staging.

Patient-Centered Approach

We focus on what each patient needs and wants. This approach boosts patient satisfaction and better outcomes.

Cutting-Edge Protocols and Technologies

We lead in medical innovation, using the latest treatments. This ensures we offer the most effective and least invasive options.

Advanced Surgical Techniques

We use the latest surgical methods, like minimally invasive surgeries. This reduces recovery times and improves results. Our surgeons are up-to-date with the latest techniques.

Innovative Treatment Modalities

We use new treatments like targeted therapy and immunotherapy. These are combined with traditional methods to fight kidney cancer effectively.

Conclusion

Knowing the size and details of a kidney tumor is key to finding the right treatment. We talked about how tumors over 7 cm are considered big. Early detection and a team approach are vital for the best results.

At livehospital.com, we stress the importance of a full treatment plan for kidney cancer. The outcome for patients depends on the tumor’s size, stage, and the patient’s health.

We offer top treatments and care standards to help patients get the best prognosis. Our team creates custom plans for each patient. This ensures they get the best care possible.

Getting a tumor treated early is very important. We urge people to see a doctor if they have symptoms or worry about their kidney health.

FAQ

What is considered a large kidney tumor?

A kidney tumor is big when it’s over 7 cm. Tumors bigger than 7 cm are T2a (7-10 cm) or T2b (>10 cm). They have a higher risk of being cancerous and need more complex treatments.

What are the different types of kidney tumors?

Kidney tumors can be either benign or malignant. Benign ones include renal cysts, angiomyolipomas, and oncocytomas. Malignant ones are mostly renal cell carcinomas (RCC), making up about 90% of kidney cancer cases.

How is kidney tumor size classified?

Kidney tumor sizes are divided into three groups: small (≤4 cm), medium (4-7 cm), and large (>7 cm). This helps doctors understand the tumor’s impact and choose the right treatment.

What is the significance of the 7 cm threshold in kidney tumors?

The 7 cm size mark is key. It separates small, localized tumors from larger, more serious ones. Tumors over 7 cm are more likely to spread and have a worse prognosis.

How are T2a and T2b kidney tumors managed?

T2a (7-10 cm) and T2b (>10 cm) tumors are treated based on size, location, and patient health. Treatments can be surgery, like radical nephrectomy, or non-surgical options like ablation therapies or active surveillance.

What are the characteristics of large kidney tumors?

Big kidney tumors are often cancerous and have aggressive features. They may also spread beyond the kidney. This makes treatment planning and prognosis more complex, needing a team approach.

How is kidney cancer diagnosed and evaluated?

Kidney cancer is found and checked with imaging like CT scans, MRI, and ultrasound. Biopsy is also used to confirm if it’s cancer. Imaging shows the tumor’s size, location, and how far it has spread.

What are the treatment approaches for large kidney tumors?

Big kidney tumors are treated with surgery, like radical nephrectomy, or non-surgical methods like ablation therapies. The choice depends on the tumor’s size, location, and the patient’s health.

What affects the prognosis and survival rates of kidney cancer patients?

Survival rates for kidney cancer patients depend on tumor size, stage, and grade. Patient health and other conditions also play a role. The 5-year survival rate varies based on when the cancer is found.

What is the multidisciplinary care approach at livehospital.com?

At livehospital.com, a team of experts works together. They include urologists, oncologists, and radiologists. This team provides top care for kidney cancer patients, focusing on patient needs and using the latest technology.

Is kidney cancer curable?

Yes, kidney cancer can be cured if caught early and treated quickly. Patients have a better chance of survival if their cancer is diagnosed early.

What is renal cell carcinoma?

Renal cell carcinoma (RCC) is the most common kidney cancer, making up about 90% of cases. It starts in the lining of the proximal convoluted tubule, a part of the kidney’s small tubes.


References

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype

https://pmc.ncbi.nlm.nih.gov/articles/PMC10240521

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01